Cedric Moreau is a Partner at Sofinnova Partners and a key member of the Crossover Strategy team. He joined the firm in June 2018, bringing 18 years of experience in life sciences investment banking. Prior to Sofinnova, Cedric was managing director and head of healthcare in the corporate finance department at Oddo BHF. In 2017, Oddo BHF was the top ranked firm for European biotech equity capital market deals. Prior to this, he was director at Bryan Garnier & Co where he completed several sizable cross-border transactions, including Galapagos, DBV, Ablynx, and Celyad. In total, he has managed more than 2 billion euros in European healthcare transactions.   

Cedric brings to the Sofinnova Crossover team and to his portfolio companies, a deep transactional expertise in the biopharma industry, as well as an extensive network of key opinion leaders, bankers and lawyers. Cedric was well known to the Sofinnova team before he came onboard, having executed several mandates for the firm’s portfolio companies.   

Before his corporate finance career, Cedric spent 10 years as a healthcare equity analyst, and was several times EXTEL top ranked (awarded for both individual and team performances) at Natixis and Fortis. He was in charge of coverage of listed biotech and pharma companies. Cedric holds a Master’s in Economics and post-graduate diploma in Finance and Taxation (Sorbonne) and diploma from the Société Française des Analystes Financiers (SFAF).